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Detachable Cook coilAbstract Objectives: Initial experience with transcatheter closure of patent ductus arteriosus
(PDA) using different types of devices is reported in Sohag University Hospital. We evaluated
the outcome, complications, and also assessed the need of surgical backup for such interventional
procedures.
Methods: From March 2011 to September 2012, 51 patients who underwent transcatheter closure
of PDA, were retrospectively identiﬁed and studied. Aortic angiogram was performed to evaluate
the size, position, and shape of the duct for appropriately choosing the occluder device type and
size. A second aortic angiogram was performed 10 min after device deployment. Echocardiography
was repeated at intervals of 24 h, then at 1, 3, and 6 months after the procedure to assess compli-
cations. The PDA was closed by Amplatzer Duct Occluder (ADO) in 40 patients, Nit occlude PFM
coil in ﬁve patients, Amplatzer muscular VSD in two patients and Detachable Cook coil in four
patients .
Results: Of 51 cases, one patient had left pulmonary artery embolization of ADO that required sur-
gical intervention. The PDA was successfully closed in 98.04% of the study population without any
residual PDA shunting. All the patients were alive. Infants made up 29% of the total patients. 45
patients were children and six patients were adults.
Conclusion: Our initial results show that transcatheter occlusion of PDA using different types of
devices is safe and effective with good midterm outcome alternative to surgery. Complications
occurred in those with unfavorable duct anatomy and presence of pulmonary hypertension. Surgi-
cal backup was not important for such interventional procedures.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Patent Ductus Arteriosus (PDA) is a common form of congen-
ital heart disease. It has been estimated to occur in 1 in 2500–
5000 live births. As an isolated lesion, it represents 9–12% of
all congenital heart diseases.1 The presence of volume overload
of the left atrium and left ventricle is an indication for closure
of the defect. Closure eliminates left to right shunt, volume
Figure 1 Descending aortogram showing large PDA size in
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hypertension and the risk of infective endocarditis.
Gross et al.2 began the era of Congenital Heart Surgery
when they reported the ﬁrst successful ligation of a Patent
Ductus Arteriosus (PDA). Porstman et.al.3 were the ﬁrst to
use a new method by which a PDA was closed successfully
by Ivalon foam plug via combined femoral artery and vein
approach. The Rashkind device4 the buttoned device,5 the
Botallocluder device6 and coils7 have been used extensively
for transcatheter closure of PDA with variable degrees of
success. Masura et al.8 had reported the use of the new
Amplatzer Duct Occluder (ADO) in humans to close the
PDA by the transcatheter approach.
Transcatheter closure of small to moderate PDA is now an
established method of treatment for most patients with PDA.9
We would like to share our experience of transcatheter closure
of PDA in Sohag University Hospital.
lateral veiw.
Figure 2 Descending aortogram showing small PDA size in
lateral view.
Figure 3 Descending aortogram showing the Amplatzer ADO in
the PDA position without shunt before its release.2. Materials and methods
All patients who had undergone transcatheter closure of
PDA between March 2011 and May 2012 in Sohag Univer-
sity Hospital were included in this retrospective study. The
patients who were selected for this device occlusion were
those with clinical and echocardiographic features of PDA
and weighed P5 kg. These patients had one or more of the
following: symptoms and signs of cardiac failure requiring
medications, failure to thrive, bounding pulses, cardiomegaly
on chest radiography and at least moderate dilation of the
left atrium and ventricle on two-dimensional (2D) echocardi-
ography. One patient had a small ventricular septal defect
(VSD); two patients had previous surgical correction for
PDA but canalization had occurred, one patient had bicuspid
aortic valve with mild aortic stenosis and moderate aortic
regurgitation and two patients had small subaortic membrane
with mild LVOT obstruction. There were a small number of
adolescents and adults who had exercise intolerance (NYHA
class II) and PDA measuring P5.0 mm at the narrowest end
on 2D echocardiography and were included for this method
of occlusion.
The patients’ clinical characteristics e.g. age, sex and weight
were recorded. Informed consents were obtained from all
patients. Aortic angiogram in lateral and right anterior oblique
views was performed to evaluate the size, position, and shape
of the duct for appropriately choosing the occluder device type
and size. The hemodynamic data including pulmonary artery
pressure and the Qp/Qs. The technique of device deployment
was similar to that reported in the literature.27,28 Detachable
or PFM coils were used for patients with small PDAs of
62.5 mm at the narrowest diameter (Fig. 1). ADOs were used
for PDAs that were >2.5 mm. ADO size selected was usually
1–2 mm larger than the duct diameter in children. (Fig. 2)10
However, some exceptions to this rule had to be made due
to unavailability of the devices at the time of procedure. The
two Amplatzer muscular VSD devices were used in type E
PDAs which had long length. A second aortic angiogram
was performed 10 min after device deployment (Figs. 3 and
4). The ﬂuoroscopy time during the procedure was identiﬁed.
The transcatheter occlusion was performed under general
anesthesia in all infants and small children or under sedation
and local anesthesia in the older patients.
Figure 4 Descending aotogram showing the Nit occlud PFM in
the PDA position without shunt before its release.
Table 2 The hemodynamic data of patients.
Hemodynamic data Mean ± SD Range
PDA size at pulmonary end (mm) 3.6 ± 1.9 1.3–8
Size of aortic ampula of PDA(mm) 11.6 ± 4.9 6–22
Systolic PA pressure (mmHg) 37.9 ± 13.1 23–72
Diastolic PA pressure (mmHg) 17.8 ± 8.34 11–32
Mean PA pressure (mmHg) 24.5 ± 9.8
Qp/QS 1.7/1 ± 1.2/1 1.2:1–3:1
Fluoroscopy time (min) 15.0 ± 11.7 5–40
Duration follow-up (months) 13 ± 8.5 2–13
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recorded. Patients had follow-up in Pediatric Cardiology
Out-patient Clinic at intervals of 24 h then 1, 3, and 6 months
after the procedure. Patients were checked clinically for any
evidence of cardiac murmur during each follow-up. Complete
echocardiographic data (left pulmonary artery and aortic
Doppler interrogation) in addition to the evaluation of resid-
ual shunting was obtained by using echocardiography machine
General Electric vivid S5.
Univariate analyses were performed by using SPSS Statis-
tics 17.0. Different devices were used, the most common were
Amplatzer duct occluder 1 and Nit occlude PFM coil. The
patients’ clinical characteristic and outcome were expressed
as mean ± standard deviation and median.
3. Results
A total of 51 patients underwent transcatheter closure of PDA
between March 2011 and September 2012. It comprised of 38
females and 13 males. The clinical proﬁles of all the patients
were shown in Table 1. There were a total of ﬁfteen patients
under 1 year old. There were six adult patients.
The clinical and hemodynamic data and results of PDA
closure are shown in Tables 1 and 2. The mean pulmonary
end of PDAs was 3.6 mm (range 1.3–8 mm) by angiography.
The mean pulmonary to systematic ﬂow ratio Qp/Qs was
1.7:1 (range 1.2:1–3:1). The procedure was successful in all
the PDAs except one patient.
Six patients had trace angiographic residual shunt with
foaming through the device with contrast jet.Table 1 The clinical proﬁle of 51 patients.
Clinical proﬁle of
51 patients
Median or % Range
Age (years) 3 7 months–35 years
Weights 11 5–80
Sex 13/38(25.5%/74.5%)The mean ﬂuoroscopy time was 15 min (range 5–20 min)
and the mean total procedure time was 33.6 min (range 20–
40 min).
This study included 15 infants, the clinical and hemody-
namic data are shown in Table 3. The mean age was
8.2 months and the mean weight was 7.6 mm kg. The mean
PDA diameter at the narrowest point was 2.3 mm.
Complication occurred in one infant in the form of ADO
embolization. One infant had large tubular PDA (type E)
which was closed by Amplatzer muscular VSD 6 mm. Another
infant had large tubular PDA without pulmonary construction
and the procedure was aborted as PDA closure required ADO
II which was unavailable in Egypt. ADO was used in thirteen
infants and PFM coil was used in two infants.
Using the classiﬁcation adopted by Krichenko et al.11,12 42
patients had type A (well- deﬁned ampulla at the aortic end
and constriction at the pulmonary artery end), two patients
had type E (long with remote constriction) and one infant
had type C PDA.
In our experience, ADO was the most common device used
in this study (87%). Our protocol in this study to use the ADO
in moderate and large PDA in children and in adult patients, is
in contrast to the Nit-Occlud PFM and Detachable Cook coils
used in small PDA. Amplatzer muscular VSD occluder was
used in two children who had PDA type E as shown in Figs. 5
and 6.
There was no evidence of obstruction of the left pulmonary
artery or the descending aorta, as conﬁrmed by 2D-Doppler in
the following day follow-up.
No patient required blood transfusion. There were two
infants who had temporary loss of femoral arterial for two
days, they received low molecular weight heparine. All the
other patients were discharged home one day after the closure
and no patient had residual shunt on Color Doppler Echocar-
diography after 24 h.Table 3 The clinical proﬁle and hemodynamic data of infant
group of patients.
Variable Mean ± SD or %
Age (months) 8.19 ± 1.79
Sex(M/F) 3/12 (/20%/80%)
Weight (kg) 7.56 ± 1.95
Pulmonary end of PDA(mm) 2.29 ± 0.79
Aortic ampula of PDA(mm) 8.2 ± 2.52
Qp/QS 1.9/1 ± 1.2/1
Figure 5 Descending aotogram showing large tubular PDA in
Lateral view.
Figure 6 Descending aortogram showing the Amplatzer mus-
cular VSD in the PDA position with foaming through device.
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There was one patient (3.3%) who experienced complication
during the procedure with Amplatzer duct occluder emboliza-
tion to the left pulmonary artery. The patient’s weight was 6 kg
with the age of 9 months and the PDA was closed with ADO
size 8/6 mm without residual shunt in second aortogram. Dur-
ing release of device, embolization occurred spontaneously.
We thought embolization occurred secondary to increased
ﬂow through the patent ductus arteriosus with possible
under-sizing of the device. The patient was referred to surgery
for device removal and closure of PDA. No catheter retrieval
was attempted.
Twenty-one out of fourty-four patients had completed
6-months and 12-month follow-up and all patients were found
to have complete closure with no evidence of device migration,
recanalization, thromboembolic episodes, wire fracture, hemo-
lysis or endocarditis.5. Discussion
PDA occurs in 9–12% of all congenital heart defects. Once the
diagnosis of the uncomplicated PDA is established, closure is
recommended by surgery or catheter occlusion to avoid pul-
monary overﬂow and prevent infective endocarditis.13,14
Transcatheter closure of PDA has been the mainstay of treat-
ment in children and adults.15 Overall PDA closure rate was 94
% and major adverse events were 1.5 %.11,12 There have been
only a few minor complications in our study compared with
the initial interventional data.16,17 Nevertheless, procedure-
associated complications have been still described in different
age groups, and they are relatively major in infants.4–6 Infor-
mation is also inadequate regarding safety and feasibility of
transcatheter closure in infants.18,19 Few studies have investi-
gated their usefulness in children weighing less than 10 kg.20,21
That meets our results which included 13 infants. The PDA
was closed successfully in 11 infants. Major complication in
the form of embolization of ADO occurred in one infant
and the procedure was aborted in another infant who had large
tubular PDA (type C).
In the present series, transcatheter closure was per-
formed in 51 patients with the PDA diameter at pulmonary
end ranging from 1.3 mm to 8 mm. The youngest age group
was 6 months old with 5 kg in weight. There were six adult
patients.
The closure rate in our study population was 98.04%, in
which one patient (3.3%) had complication of ADO emboliza-
tion and the child was referred to cardiac surgery and the
procedure was aborted in one infant due to unavailability of
ADO type II. ADO embolization is a well known complication
especially in early experience of any cardiac center. This com-
plication has been described in many series.5–28
Coil is still the preferred device in a small PDA (less than
2.5 mm).29,30 In our study, two types of coils were used: Nit oc-
clude PFM coil in ﬁve patients and Detachable Cook coil in
four patients. The ADO was used in moderate and large PDA.
However in our study, there is no protrusion of the occlu-
sion device into the aorta or obstruction to the LPA which
are common complications of transcatheter closure of
PDA.22–24
The results documented in our series are in accordance with
the results reported in many other interventional pediatric
cardiac centers around the world.25–28
There are many advantages of PDA device closure
compared to surgical ligation which include, less invasive,
without surgical scar, short hospital course, low morbidity
and comparable success rate. However, the surgical ligation
is still necessary for large PDA especially in small infants.6. Conclusion
Our experience with transcatheter closure of PDA is effec-
tive and safe with good mid-term outcome, as reported by
various interventional pediatric cardiology centers around
the world.
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